Evidence map›Paper›PMID 33468465›Full record

ArticleAntimicrobial agents and chemotherapy2021

Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.

G L Drusano, Stephanie Rogers, David Brown, C A Peloquin, Michael Neely, Walter Yamada, Sarah Kim, Mohammed Almoslem, Stephan Schmidt, Arnold Louie

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Analyzing Pharmacodynamic Count Data That Rapidly Decrease to Zero.CPT: pharmacometrics & systems pharmacology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

G L DrusanoInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA gdrusano@ufl.edu.ORCID 0000-0001-9162-7332
Stephanie RogersInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
David BrownInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
C A PeloquinInfectious Diseases Pharmacodynamics Laboratory, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-9002-7052
Michael NeelyUniversity of Southern California, Los Angeles Children's Hospital, Los Angeles, California, USA.
Walter YamadaUniversity of Southern California, Los Angeles Children's Hospital, Los Angeles, California, USA.
Sarah KimCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.ORCID 0000-0002-9179-0735
Mohammed AlmoslemCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.
Stephan SchmidtCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.
Arnold LouieInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
University of Florida · USUniversity of Southern California · US

Funding

Optimizing Combination Therapy to Accelerate Clinical Cure of TuberculosisP01AI123036 · NIAID · UNIVERSITY OF FLORIDA · PI DRUSANO, GEORGE LOUIS · 2016 to 2020
$12.0M
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosaR01AI121430 · NIAID · UNIVERSITY OF FLORIDA · PI DRUSANO, GEORGE LOUIS, LOUIE, ARNOLD · 2016 to 2020
$4.1M
NIAID NIH HHS P01 AI123036NIAID NIH HHS R01 AI121430
6 · The paper itself

Abstract

The repurposed agent moxifloxacin has become an important addition to the physician's armamentarium for the therapy of

Indexed as

Antitubercular AgentsTuberculosisArea Under CurveFluoroquinolonesHalf-LifeHumansMicrobial Sensitivity TestsMoxifloxacinAntitubercular AgentsFluoroquinolonesMoxifloxacindose fractionationmathematical modelingMycobacterium tuberculosispharmacodynamicsresistance suppression

Identifiers

PMID33468465
PMCPMC8097450
OpenAlexW3122138709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.